SCHEMBL10243931

SCHEMBL10243931

CCN(CCNC(=O)OC)C(C)c1cc(C)nn1C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 3/20 0.33
CCNE1 P24864 2/20 0.33
CDK2 P24941 2/20 0.33
GSK3B P49841 1/20 0.33
SMN1; SMN2 Q16637 3/20 0.32
SMPD3 Q9NY59 1/20 0.32
ALDH1A1 P00352 6/20 0.32
CYP3A4 P08684 3/20 0.32
CYP1A2 P05177 2/20 0.32
CYP2C19 P33261 2/20 0.32
CYP2C9 P11712 1/20 0.32
HPGD P15428 1/20 0.31
FLT3 P36888 1/20 0.31
SYK P43405 1/20 0.31
POLB P06746 3/20 0.31
LMNA P02545 2/20 0.31
APAF1 O14727 1/20 0.31
FFAR1 O14842 1/20 0.31
GAA P10253 1/20 0.30
MEN1 O00255 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10244467 0.80 GAA (0.34) CYP2D6ALDH1A1LMNAGAATP53
SCHEMBL10243567 0.80 TAS1R3 (0.34) CYP2D6GAAKMT2A
SCHEMBL10243738 0.77 SMN1; SMN2 (0.35) CYP2D6SMN1; SMN2ALDH1A1CYP3A4CYP1A2
SCHEMBL10243651 0.76 RAB9A (0.34) CYP2D6SMN1; SMN2ALDH1A1CYP1A2HPGD
SCHEMBL10243922 0.74 RAB9A (0.35) SMN1; SMN2ALDH1A1HPGDGAAMEN1
SCHEMBL10243497 0.74 SLC22A1 (0.43) CYP2D6SMN1; SMN2ALDH1A1CYP3A4CYP1A2
SCHEMBL10244359 0.74 ALDH1A1 (0.41) SMN1; SMN2ALDH1A1HPGDPOLBLMNA
SCHEMBL10244313 0.74 LMNA (0.35) SMN1; SMN2ALDH1A1CYP1A2CYP2C19HPGD
SCHEMBL10243510 0.73 ALOX5 (0.40) SMN1; SMN2ALDH1A1LMNA
SCHEMBL10244310 0.72 MTNR1A (0.33) CYP2D6ALDH1A1CYP3A4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 CYP2D6 1574/4885CCNE1 3629/4885CDK2 4286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.